UPADACITINIB
upadacitinib 15 mg modified release tablet, 28
UPADACITINIB (13350P)
13350P
Manner of administration:Oral
Restriction
Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial treatment - Initial 1 (New patient)
Restriction
Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial treatment - Initial 2 (Change or recommencement of treatment after a break
in biological medicine of less than 5 years)
Restriction
Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial treatment - Initial 3 (Recommencement of treatment after a break in biological
medicine of more than 5 years)
Restriction
Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a
break in biological medicine of less than 5 years) or Initial 3 (Recommencement of
treatment after a break in biological medicine of more than 5 years) - balance of
supply
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 3 | DPMQ: $1,212.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Rinvoq | |||||